Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGunsynd Regulatory News (GUN)

Share Price Information for Gunsynd (GUN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.14
Bid: 0.13
Ask: 0.15
Change: 0.00 (0.00%)
Spread: 0.02 (15.385%)
Open: 0.14
High: 0.14
Low: 0.14
Prev. Close: 0.14
GUN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Investment – Aberdeen Minerals

16 Jan 2023 10:09

RNS Number : 8347M
Gunsynd PLC
16 January 2023
 

Gunsynd plc

 

("Gunsynd" or the "Company")

 

New Investment - Aberdeen Minerals

 

Gunsynd Plc (AIM: GUN, AQSE: GUN) is pleased to announce that it has invested £150,000 into Strategic Minerals Europe Ltd, the parent company of Aberdeen Minerals Ltd (together "Aberdeen"), a UK company exploring for Nickel-Copper-Cobalt deposits in North East Scotland, as part of a private funding round supported by new and existing shareholders and the Board of Aberdeen.

 

The investment in Aberdeen was executed on the following terms: subscription for 2,000,000 ordinary shares at 7.5 pence per share for a total consideration of £150,000 from the Company's existing cash resources;

Gunsynd's investment is a part of a £1.1 million capital raising supported by new and existing investors and the Board of Aberdeen.

· Gunsynd will hold approximately 2.75% of the issued share capital of Aberdeen following this capital raising;

 

· Immediately following this capital raising Aberdeen will have 72,856,531 Ordinary shares in issue;

 

· Subject to the approval by Aberdeen's shareholders, a further 2,933,332 Ordinary shares are expected to be issued to founding shareholders and the directors of Aberdeen, resulting in an expected total issued share capital of 75,789,863 ordinary shares, of which Gunsynd plc would hold 2.64%, and a pro-forma equity valuation of £5.7 million;

 

· Aberdeen will utilise the funds for:

diamond drilling programme at the flagship Arthrath Project

downhole geophysics

development of its land portfolio

general exploration and working capital requirements.

 

· Aberdeen has plans for an IPO on either the ASX or AIM market(s) targeted during 2023 subject to favourable market conditions.

 

· For the year ended 31 March 2022, Aberdeen had turnover of nil and made a loss of £426,548.

 

About Aberdeen Minerals Ltd:

 

North East Scotland is a district scale opportunity for nickel-copper-cobalt sulphide exploration, which has attracted major mining companies - including Rio Tinto and Inco - in past decades to this part of Scotland. The UK currently has no domestic production of nickel, copper or cobalt and has a renewed focus on maximising its own home grown potential to produce minerals essential to the energy transition including the publication in July 2022 of the UK Government's first ever Critical Minerals Strategy.

Aberdeen has recently flown phase one of an airborne electromagnetic ("EM") and magnetic geophysical survey in North-East Scotland. Initial findings are being used to assist drill targeting at the Arthrath Project, and also assess a target pipeline across the broader district.

At Arthrath, a historical estimate of 17 million tonnes grading 0.21% Ni and 0.14% Cu (not JORC compliant; see Note 1 below) has been reported at one of several mineralized zones on only a small portion of a 7 kilometre feeder dyke structure which remains largely untested by effective drilling. Aberdeen is particularly interested in targeting higher grade zones within the system that have previously been reported. 

Aberdeen's plans for Arthrath include a diamond drilling programme to validate historical results and outline a JORC Exploration Target (specified range of tonnage and grade) ahead of a potential IPO which would seek funds to drill out an initial resource and follow up on the regional EM targets. 

Aberdeen believes it has established a first-mover land position over the past 4 years that is difficult and costly to replicate, positioning Aberdeen as a credible base metals explorer in Scotland. 

More information can be found on Aberdeen's website: www.aberdeenminerals.com

 

Peter Ruse, a director of Gunsynd, commented: "Gunsynd is pleased to have the opportunity to add this exciting Nickel, copper and cobalt exploration company to its portfolio. Aberdeen offers exposure to key critical metals (Nickel, Copper, Cobalt) exploration in the United Kingdom amongst a strong backdrop of fundamental drivers for the underlying commodities and policy change in the UK. Aberdeen has an experienced Board of directors and UK based management team who we believe have demonstrated value creation in past and present company roles. We are very excited by the active exploration programmes which will be carried out on the Aberdeen projects kicking off early in 2023."

 

Note 1

Tonnage and grade estimates are historical in nature, uncertain and have not been reported in accordance with the JORC Code (2012).

 

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the Company's ability to execute and implement future plans, and the occurrence of unexpected events. Actual results achieved may vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors.

 

For further information please contact:

 

Gunsynd plc

Hamish Harris/ Peter Ruse

 

 

+44 (0) 78 7958 4153

Cairn Financial Advisers LLP

James Caithie / Liam Murray

 

+44 (0) 20 7213 0880

 

Peterhouse Capital Limited

Lucy Williams

 

+44 (0) 20 7469 0936

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCGZGMMGVFGFZM
Date   Source Headline
6th Dec 20129:57 amRNSForm 8.5 (EPT/NON-RI)
6th Dec 20127:00 amRNSApproval of Opening Position Disclosure
5th Dec 201211:11 amRNSForm 8.5 (EPT/NON-RI)
4th Dec 201211:53 amRNSForm 8.5 (EPT/NON-RI)
3rd Dec 201212:19 pmRNSForm 8.3 - [Evocutis PLC]
3rd Dec 20127:00 amRNSStrategic Review
3rd Dec 20127:00 amRNSFinal Results
23rd Nov 20127:00 amRNSNotice of Results
5th Nov 20127:00 amRNSIssue of Equity
21st Sep 20127:00 amRNSTR-1 Notification of Major Interest in Shares
8th Aug 201212:24 pmRNSUpdate on commencement of dealings
1st Aug 20127:00 amRNSIssue of Equity and Grant of Share Options
21st Jun 20127:00 amRNSTrading Update
30th Apr 20127:00 amRNSDirectorate Change
4th Apr 20127:00 amRNSDirectorate Change
22nd Mar 20127:00 amRNSInterim Results
29th Feb 20127:00 amRNSNotification of Results
27th Jan 20127:00 amRNSEvocutis validates anti-ageing LabSkinT model
24th Jan 20121:35 pmRNSResult of AGM
13th Jan 20127:00 amRNSEvocutis Opens State-of-the-art laboratory
23rd Dec 20117:00 amRNSDirector/PDMR Shareholding
15th Dec 20117:00 amRNSNotice of AGM and Report and Accounts
29th Nov 20117:00 amRNSPreliminary Results
28th Nov 20117:00 amRNSEvocutis launches antimicrobial LabSkinT model
20th Oct 20115:03 pmRNSResult of GM and Change of Name to Evocutis plc
30th Sep 20117:00 amRNSBusiness Update
27th Sep 20117:00 amRNSPosting of Circular and Notice of General Meeting
8th Jul 20117:00 amRNSChange of Registered Office
21st Jun 201111:00 amRNSDirectorate Change
23rd May 201111:45 amRNSResult of General Meeting
11th May 201111:17 amRNSDirector's Dealing
6th May 20117:00 amRNSAcquisition and Placing to raise £2 million
27th Apr 20112:30 pmRNSBusiness Update
8th Mar 20117:00 amRNSInterim Results
2nd Mar 20113:12 pmRNSHolding(s) in Company
25th Feb 20117:00 amRNSHolding(s) in Company
20th Jan 20111:23 pmRNSResult of AGM
17th Jan 20117:00 amRNSSyntopix to research biofilms for Beiersdorf AG
14th Jan 201110:13 amRNSPosting of Annual Report and notice of AGM
3rd Dec 20107:00 amRNSGrant of share options to Directors
29th Nov 20107:00 amRNSFinal Results
11th Nov 20107:00 amRNSAppointment of Broker
1st Nov 20107:00 amRNSSecond Agreement with Sinclair Pharma
29th Sep 20105:05 pmRNSHolding(s) in Company
27th Sep 20102:51 pmRNSHolding(s) in Company
23rd Aug 20107:00 amRNSAgreement with Global Consumer Products Company
22nd Jun 20103:20 pmRNSDirectorate Change
22nd Apr 20107:00 amRNSAgreement with Sinclair Pharma plc
31st Mar 201011:25 amRNSResult of General Meeting
15th Mar 201011:08 amRNSProposed Fundraising

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.